Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

FDA Approves Alzheimer’s Drug Leqembi

The drug slows the progression of Alzheimer’s, but comes with a severe box warning about potentially lethal side effects.

Leqembi
leqembi

An NBC News article noted the FDA’s recent clearance of the Alzheimer's drug Leqembi, the first of its kind to receive full regulatory approval. However, it comes with a strong safety warning about potentially life-threatening side effects. Leqembi, developed by Japanese drugmaker Eisai and U.S.-based Biogen, targets beta-amyloid, a protein believed to be an underlying cause of Alzheimer's. In a phase 3 clinical trial, the drug demonstrated a 27% slowing of disease progression over 18 months. 

FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?
Break out of the ordinary: see what’s new in life sciences packaging
<strong>At PACK EXPO Las Vegas, you’ll see machinery in action and new tech from 2,300 suppliers, collaborate with experts and explore transformative solutions. Join us in September to experience a breakthrough for life sciences products.</strong>
REGISTER NOW & SAVE!
Break out of the ordinary: see what’s new in life sciences packaging